Brought to you by:
VEITH 2021: Two-year follow-up data from EVAS2 IDE study delivered
The confirmatory EVAS2 clinical study to evaluate the safety and effectiveness of Endologix’s Nellix endovascular aneurysm sealing system (EVAS) for the treatment of infrarenal abdominal aortic aneurysms (AAAs) contains positive two-year follow-up data, the leading investigator has revealed. A first…
Viz.ai reveals launch of new AI-powered modules for pulmonary embolism, aortic disease
Viz.ai—a company focused on artificial intelligence (AI)-driven intelligent care coordination—today announced the U.S. commercial launch of its AI-powered modules for pulmonary embolism (PE) and aortic disease at the 2021 VEITHsymposium (Nov. 16–20) in Orlando, Florida. The new modules allow for…
SVS branding campaign wins communications award
The Society for Vascular Surgery (SVS) branding campaign has received a “Profiles of Excellence Award” from the American Association of Medical Society Executives for outstanding achievement by medical societies. The SVS won its award in the communications category, for “initiatives…
SVS president presents point-by-point defense of Society position on paclitaxel controversy
NEW YORK—Kim Hodgson, MD, president of the Society for Vascular Surgery, delivered a robust defense of the SVS position on the drug-coated balloon (DCB) and drug-eluting stent (DES) issue that is currently enveloping the vascular community during the 2019 iteration…
Vascular Specialist performs key role as conduit of discussion, says chief editor, as newspaper changes publisher
NEW YORK—Vascular Specialist has a critical role to play in dictating discussion of the key issues that impact surgeons in the field, the publication’s medical editor told a gathering at the 2019 VEITHsymposium held Nov. 19-23 in New York. The…